Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report
Until recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000//hbT.OH.2022.11.064 |